scleroderma. in the name of god the merciful the compassionate
TRANSCRIPT
Scleroderma
In the name of God
the merciful
the compassionate
Classification of Scleroderma:
Localized SclerodermaLocalized Scleroderma
• No visceral involvementNo visceral involvement
• No Typical hand involvementNo Typical hand involvement
• No Raynaud’s ph.No Raynaud’s ph.
• No Auto-Antibody positivityNo Auto-Antibody positivity
• Only sclerosisOnly sclerosis of one or more skin areaof one or more skin area
Systemic Scleroderma (SSc)Systemic Scleroderma (SSc)
Salehi I.Salehi I.
•SclerodermaScleroderma
Localized Scleroderma: Morphea:Morphea:
• Plaque morpheaPlaque morphea
• Guttate morpheaGuttate morphea
• Generalized morpheaGeneralized morphea
• Bullous morpheaBullous morphea
• Deep morpheaDeep morphea
Linear SclerodermaLinear Scleroderma
Salehi I.Salehi I.
•SclerodermaScleroderma
Plaque morphea: Local sclerosis in Local sclerosis in << 2 anatomic sites 2 anatomic sites
Salehi I.Salehi I.
•SclerodermaScleroderma
Plaque morphea:Local sclerosis in Local sclerosis in << 2 anatomic sites 2 anatomic sites
Salehi I.Salehi I.
•SclerodermaScleroderma
Generalized morphea: Skin sclerosis in Skin sclerosis in >> 3 anatomic sites 3 anatomic sites
Salehi I.Salehi I.
•SclerodermaScleroderma
Linear Scleroderma:
• ChildrenChildren
• Growth impairment of the involved Growth impairment of the involved
extremityextremity
• Dermatomal distributionDermatomal distribution
• En coup de sabreEn coup de sabre
Salehi I.Salehi I.
•SclerodermaScleroderma
Salehi I.Salehi I.
•SclerodermaScleroderma
Salehi I.Salehi I.
•SclerodermaScleroderma
Salehi I.Salehi I.
•SclerodermaScleroderma
Salehi I.Salehi I.
•SclerodermaScleroderma
Systemic Sclerosis (SSc)Systemic Sclerosis (SSc)
Definition:Definition:
• Multisystem, Chronic, AutoimmuneMultisystem, Chronic, Autoimmune
• Overproduction of collagen fibersOverproduction of collagen fibers
• Thickened & sclerotic skinThickened & sclerotic skin
• Raynaud’s phenomenonRaynaud’s phenomenon
• Visceral organ involvement (fibrosis)Visceral organ involvement (fibrosis)
Salehi I.Salehi I.
•SclerodermaScleroderma
Epidemiology:• Annual incidence in USA: 1-2 / 100,000Annual incidence in USA: 1-2 / 100,000
• Peak onset age: 30-50 y/oPeak onset age: 30-50 y/o
• 100 RA, 10 SLE, 1 Scl100 RA, 10 SLE, 1 Scl
• F/M ratio: 3/1F/M ratio: 3/1
• Black > other raceBlack > other race
• Rare in childrenRare in children
• Rare in men < 30 y/oRare in men < 30 y/o
Salehi I.Salehi I.
•SclerodermaScleroderma
Clinical staging of SSc:Clinical staging of SSc:
Inflammatory stage:Inflammatory stage:• Early, Edematous phaseEarly, Edematous phase• Arthralgia, Soft tissue swellingArthralgia, Soft tissue swelling• Mistake for RA & other CTDMistake for RA & other CTD
Indurative stage:Indurative stage:• Intermediate fibrotic phaseIntermediate fibrotic phase• Hardness & thickness of skinHardness & thickness of skin• Typical clinical featuresTypical clinical features
Atrophic stage:Atrophic stage:• Late phaseLate phase• Very thin skinVery thin skin
Salehi I.Salehi I.
•SclerodermaScleroderma
Clinical classification of SSc:
• DiffuseDiffuse Cutaneous Cutaneous SclScleroderma (dcSSc)eroderma (dcSSc)
• LimitedLimited Cutaneous Cutaneous SclScleroderma (lcSSc)eroderma (lcSSc)
• Systemic Sclerosis Systemic Sclerosis sine Sclsine Sclerodermaeroderma
• OverlapOverlap syndrome syndrome
• Pre-SclPre-Scleroderma or eroderma or Early SclEarly Sclerodermaeroderma
Salehi I.Salehi I.
•SclerodermaScleroderma
Limited Cutaneous Scleroderma:
Distal portion of extremities plusHead & neck
Acrofacial
Salehi I.Salehi I.
•SclerodermaScleroderma
Diffuse Cutaneous Scleroderma:Diffuse Cutaneous Scleroderma:
Distal + ProximalDistal + ProximalHead & NeckHead & NeckTrunkTrunk
TrunkalTrunkal
Salehi I.Salehi I.
•SclerodermaScleroderma
Intermediate Cutaneous Scl.Intermediate Cutaneous Scl.
Salehi I.Salehi I.
•SclerodermaScleroderma
Attention please:
• Almost all patients have skin Almost all patients have skin
involvement in the:involvement in the:
• FingersFingers: sclerodactyly: sclerodactyly
• HandsHands and and
• FaceFace
Salehi I.Salehi I.
•SclerodermaScleroderma
Pathogenesis:Pathogenesis:• UnknownUnknown• Genetic BackgroundGenetic Background• Environmental trigger factors (Ags) Environmental trigger factors (Ags) • Vascular events:Vascular events:
• Raynaud’s ph.Raynaud’s ph.• Endothelial injuryEndothelial injury
• Immunological events (autoimmunity)Immunological events (autoimmunity)• CellularCellular• HumoralHumoral
• Activated fibrogenic fibroblastActivated fibrogenic fibroblast
Salehi I.Salehi I.
•SclerodermaScleroderma
Genetic considerations:Genetic considerations:
• Non-Mendelian pattern of inheritanceNon-Mendelian pattern of inheritance
• Concordance rate of 4.7% in Monozygotic Concordance rate of 4.7% in Monozygotic
twinstwins
• Positive family history of 1.6% in First Positive family history of 1.6% in First
degree relativedegree relative
• Multiple Genetic loci Multiple Genetic loci
Salehi I.Salehi I.
•SclerodermaScleroderma
Multiple Genetic loci:Multiple Genetic loci:• Genes encoding ACEGenes encoding ACE
• Genes encoding endothelin-1 Genes encoding endothelin-1
• Genes encoding NOSGenes encoding NOS
• Genes encoding CD19Genes encoding CD19
• Genes encoding monocyte chemoattractant Genes encoding monocyte chemoattractant
protein-1protein-1
• Genes encoding STAT4, IRF5, CTGF, SPARCGenes encoding STAT4, IRF5, CTGF, SPARC
Salehi I.Salehi I.
•SclerodermaScleroderma
Environmental Antigenic triggers:
• Viruses:Viruses:
– Human CMV, and Parvovirus B19Human CMV, and Parvovirus B19
– Antitopoisomerase-I (Scl-70) recognize antigenic Antitopoisomerase-I (Scl-70) recognize antigenic
epitopes of the hCMV: epitopes of the hCMV: Molecular mimicryMolecular mimicry
• Silica:Silica:
– The incidence of SSc is increased among The incidence of SSc is increased among
miners exposed to silicaminers exposed to silica
Salehi I.Salehi I.
•SclerodermaScleroderma
Environmental Antigenic triggers:
• Polyvinyl chloride, Epoxy resins, Polyvinyl chloride, Epoxy resins,
Aromatic hydrocarbons (toluene,…)Aromatic hydrocarbons (toluene,…)
• Cu, FeCu, Fe: :
– Treatment with D-penicillamineTreatment with D-penicillamine
• DrugsDrugs: :
– Bleomycin, Pentazocine & CocaineBleomycin, Pentazocine & Cocaine
Salehi I.Salehi I.
•SclerodermaScleroderma
Vascular events:
• Upon Upon Raynaud’s phenomenonRaynaud’s phenomenon
• Viruses, superoxide radicals, auto-antibodies,…(Viruses, superoxide radicals, auto-antibodies,…(AgsAgs))
Endothelial injury Endothelial injury
• Endothelial injury Endothelial injury endothelium-derived endothelium-derived vasoconstrictorvasoconstrictor
((Endothelin-1Endothelin-1)) increases increases and endothelium-derived and endothelium-derived
vasodilators vasodilators ((NO, ProstacyclinNO, Prostacyclin)) decrease decrease
Salehi I.Salehi I.
•SclerodermaScleroderma
Vascular events:• Vascular injury Vascular injury Increased expression of ICAM-1 Increased expression of ICAM-1 and other and other
AMsAMs
• Vascular injury Vascular injury Platelet aggregation Platelet aggregation release of Serotonin, release of Serotonin,
Thromboxane, and PDGF Thromboxane, and PDGF
• Defective fibrinolysisDefective fibrinolysis
• Microvessels show Microvessels show enhanced permeability enhanced permeability andand leukocyte leukocyte
diapedesis diapedesis
Salehi I.Salehi I.
•SclerodermaScleroderma
Vascular events:
• Ischemia-reperfusion Ischemia-reperfusion Reactive oxygen species Reactive oxygen species
(ROS) (ROS) further damage the endothelium further damage the endothelium
• Defective revascularization Defective revascularization despite elevated levels despite elevated levels
of Vascular endothelial growth factor (VEGF) and of Vascular endothelial growth factor (VEGF) and
other angiogenic factorsother angiogenic factors
Salehi I.Salehi I.
•SclerodermaScleroderma
Vascular events:
• The number of The number of endothelial progenitor cells is reducedendothelial progenitor cells is reduced
in circulation, and their differentiation into mature in circulation, and their differentiation into mature
endothelial cells is impaired endothelial cells is impaired Wide spread Wide spread capillary capillary
malformation and lossmalformation and loss, , obliterative vasculopathyobliterative vasculopathy of of
small and medium-sized arteries, and failure to repair small and medium-sized arteries, and failure to repair
damaged vessels are damaged vessels are hallmarks of SSchallmarks of SSc
Salehi I.Salehi I.
•SclerodermaScleroderma
Vascular events:• Myointimal cells proliferate, Basement membrane is Myointimal cells proliferate, Basement membrane is
thickened and fibrosis of the adventitial layers developsthickened and fibrosis of the adventitial layers develops
• Occlusive vasculopathyOcclusive vasculopathy affects capillaries arterioles and affects capillaries arterioles and
even large vessels in many organs even large vessels in many organs reduced blood reduced blood
flow, flow, tissue ischemia tissue ischemia generation of generation of profibrotic factorsprofibrotic factors..
Salehi I.Salehi I.
•SclerodermaScleroderma
Vascular events:
• Vascular injury Vascular injury Leukocyte Recruitment Leukocyte Recruitment
• Leukocyte Recruitment Leukocyte Recruitment Th2 cytokines Th2 cytokines
• Th2 cytokines Th2 cytokines Fibroblast activation Fibroblast activation
• Leukocyte Recruitment Leukocyte Recruitment Auto-Antibodies Auto-Antibodies
• Auto-Antibodies Auto-Antibodies Vascular injury Vascular injury
• Auto-Antibodies Auto-Antibodies Fibroblast activation Fibroblast activation
Salehi I.Salehi I.
•SclerodermaScleroderma
Vascular events:
• Initial vascular injury in a genetically susceptible Initial vascular injury in a genetically susceptible
individual leads to functional and structural vascular individual leads to functional and structural vascular
alterations, inflammation and autoimmunityalterations, inflammation and autoimmunity
• Inflammatory and immune responses initiate and sustain Inflammatory and immune responses initiate and sustain
fibroblast activation and differentiation, resulting in fibroblast activation and differentiation, resulting in
pathologic fibrogenesis and irreversible tissue damagepathologic fibrogenesis and irreversible tissue damage
Salehi I.Salehi I.
•SclerodermaScleroderma
Vascular events:
• Progressive luminal occlusionProgressive luminal occlusion
• Persistent endothelial cell damagePersistent endothelial cell damage
• Adventitial fibrosis Adventitial fibrosis
• Establish a Establish a vicious cyclevicious cycle
Salehi I.Salehi I.
•SclerodermaScleroderma
Fibrosis events:
• Fibroblast activation & Tissue hypoxia Fibroblast activation & Tissue hypoxia
– Collagen accumulationCollagen accumulation
– Extracellular matrix reorganizationExtracellular matrix reorganization
– Impaired matrix degradationImpaired matrix degradation
Tissue fibrosisTissue fibrosis
Salehi I.Salehi I.
•SclerodermaScleroderma
Fibrosis events:
• Fibrogenic phenotype fibroblasts:Fibrogenic phenotype fibroblasts:
– ““Scleroderma phenotype” Scleroderma phenotype”
• Uncontrolable production of collagenUncontrolable production of collagen
Salehi I.Salehi I.
•SclerodermaScleroderma
Autoimmunity:
• Auto-antibodiesAuto-antibodies
• Animal modelsAnimal models
• Lymphocytes & AECA Lymphocytes & AECA Apoptosis of Apoptosis of
endothelial cellsendothelial cells
Salehi I.Salehi I.
•SclerodermaScleroderma
Host susceptibility for SSc:
• Compatible Genetic backgroundCompatible Genetic background
• Basal Vasculopathy:Basal Vasculopathy:
• Basal Immunologic abnormalities and Basal Immunologic abnormalities and
Autoimmunity: Cellular, HumoralAutoimmunity: Cellular, Humoral
• ““Scleroderma phenotype” of fibroblastsScleroderma phenotype” of fibroblasts
Salehi I.Salehi I.
•SclerodermaScleroderma
Basal Vasculopathy:Basal Vasculopathy:
• Raynaud’s phRaynaud’s ph.: highly sensitive alpha-2 adrenergic receptors on vascular smooth-.: highly sensitive alpha-2 adrenergic receptors on vascular smooth-
muscle cells muscle cells
• Vascular endothelium has potential of Vascular endothelium has potential of easy injuryeasy injury and and dysregulation dysregulation platelet platelet
aggregation aggregation
• Endothelium-derived Endothelium-derived vasoconstrictorsvasoconstrictors increasesincreases and and vasodilators decrease vasodilators decrease
luminal occlusionluminal occlusion
• Endothelial cells Endothelial cells overexpress ICAM-1overexpress ICAM-1 and other AMs and other AMs facilitate leukocyte facilitate leukocyte
diapedesisdiapedesis
• Reduced Endothelial progenitor cellsReduced Endothelial progenitor cells with impaired differentiation with impaired differentiation defective defective
revascularizationrevascularization
Salehi I.Salehi I.
•SclerodermaScleroderma
Host susceptibility:
Basal Cellular Autoimmunity:Basal Cellular Autoimmunity:
• CD4(+) T cells CD4(+) T cells have elevated levels of have elevated levels of alpha-1 Integrin AMs alpha-1 Integrin AMs
enhanced ability to bind to endothelium & to fibroblastsenhanced ability to bind to endothelium & to fibroblasts
• Activated Macrophages & T cells show Activated Macrophages & T cells show Th2 immune responseTh2 immune response & &
secrete IL-4 & IL-13secrete IL-4 & IL-13
• Th2 cytokines Th2 cytokines production of production of TGF-B TGF-B collagen synthesis collagen synthesis
• TGF-B stimulates its own synthesis, as well as that of CTGF. TGF-B stimulates its own synthesis, as well as that of CTGF.
SoTGF-B establishes an autocrine/paracrine stimulatory loop that SoTGF-B establishes an autocrine/paracrine stimulatory loop that
sustains activation of fibroblastssustains activation of fibroblasts
• DefectiveDefective immunosuppressive function of immunosuppressive function of Regulatory T cells Regulatory T cells
(Tregs) (Tregs) loss of immune Tolerance loss of immune Tolerance
• B cells B cells TGF-B & Autoantibadies TGF-B & Autoantibadies
Salehi I.Salehi I.
•SclerodermaScleroderma
Host susceptibility:
Basal Humoral Autoimmunity:Basal Humoral Autoimmunity:
• Antinuclear antibodiesAntinuclear antibodies (ANA) in virtualy all patients: (ANA) in virtualy all patients:
Anti-topoisomerase-I (Anti-topoisomerase-I (Scl-70Scl-70))
Anti-centromere antibody (Anti-centromere antibody (ACAACA))
Anti Anti RNA polymerases RNA polymerases antibodyantibody
• Anti-fibroblasts Ab (Scl-70 ?), AECA, Anti-PDGF Anti-fibroblasts Ab (Scl-70 ?), AECA, Anti-PDGF
receptor Ab, Anti-fibrillin & Anti MMP Abreceptor Ab, Anti-fibrillin & Anti MMP Ab
• Proteolytic cleavage, increased expression, and Proteolytic cleavage, increased expression, and
altered localization of cellular proteins in SSc altered localization of cellular proteins in SSc
proteins are recognized as proteins are recognized as neoepitopesneoepitopes by B cells by B cells
Salehi I.Salehi I.
•SclerodermaScleroderma
Host susceptibility:
• ““Scleroderma phenotype” of fibroblasts:Scleroderma phenotype” of fibroblasts:
• In SSc in addition to resident fibroblasts, epithelial In SSc in addition to resident fibroblasts, epithelial
cells and endothelial cells can differentiate into cells and endothelial cells can differentiate into
myofibroblastsmyofibroblasts
• In SSc circulating mesanchymal progenitor cells of In SSc circulating mesanchymal progenitor cells of
bone marrow origin contribute to fibrosisbone marrow origin contribute to fibrosis
• Fibroblasts of SSc are Fibroblasts of SSc are “Scleroderma phenotype”“Scleroderma phenotype”::
Enhanced secretion Enhanced secretion of collagen, cytokines & growth factorsof collagen, cytokines & growth factors
ExpressionExpression of chemokine receptors and cell of chemokine receptors and cell surface AMssurface AMs
Resistance to apoptosisResistance to apoptosis
Autocrine TGF-B signalingAutocrine TGF-B signaling
Salehi I.Salehi I.
•SclerodermaScleroderma
Host susceptibility:
Senario of pathophysiology:
• In a susceptible individual, Complex In a susceptible individual, Complex
interplay between basal vasculopathy interplay between basal vasculopathy
and autoimmunity affects on fibrogenic and autoimmunity affects on fibrogenic
fibroblasts and initiate and amplify the fibroblasts and initiate and amplify the
fibrotic process fibrotic process
Salehi I.Salehi I.
•SclerodermaScleroderma
Vascular involvement:Vascular involvement:
Early stage: Early stage: • Reversible vasospasm in arteriolesReversible vasospasm in arterioles
• Transient Raynaud ph.Transient Raynaud ph.
Intermediate stage:Intermediate stage:• Vasospasm + mild to moderate fixed stenosis Vasospasm + mild to moderate fixed stenosis
• Prolonged RP and digital ischemia and ulceration Prolonged RP and digital ischemia and ulceration
Late stage:Late stage:• Severe fixed stenosisSevere fixed stenosis
• Digital infarction and auto-amputation Digital infarction and auto-amputation
Salehi I.Salehi I.
•SclerodermaScleroderma
Classic case of SSc:Classic case of SSc: A middle age woman with:A middle age woman with:
• Raynaud’s phRaynaud’s ph
• Skin hardness, hyper-hypopigmentationSkin hardness, hyper-hypopigmentation
• Masked face, telangiectasia, Micro-ostiaMasked face, telangiectasia, Micro-ostia
• Sclerodactyly, Pitting ulcerSclerodactyly, Pitting ulcer
• Dysphagia, Pyrosis, DiarrheaDysphagia, Pyrosis, Diarrhea
• Dyspnea on exersion, dry coughDyspnea on exersion, dry cough
• Arthralgia, myalgiaArthralgia, myalgia
Salehi I.Salehi I.
•SclerodermaScleroderma
General manifestations:General manifestations:
Most frequent:
• Fatigue, Stiff joints
• Loss of strength, Pain
• Sleep difficulties
• Skin discoloration
Less frequent:
• Breathlessness, depression, sore eyes
• Upset stomach, nausea, weight loss
Salehi I.Salehi I.
•SclerodermaScleroderma
Raynaud phenomenon (RP):Raynaud phenomenon (RP):
Definition:Definition: Sequential color changes in Sequential color changes in
the digits due to arterial vasoconstriction, the digits due to arterial vasoconstriction,
precipitated by cold, stress, a decrease in precipitated by cold, stress, a decrease in
temperature and vibration.temperature and vibration.
Epidemiology:Epidemiology:
• 3-5% of general population3-5% of general population
• More frequent in women More frequent in women
Salehi I.Salehi I.
•SclerodermaScleroderma
Raynaud phenomenon (RP):Raynaud phenomenon (RP):
Triphasic color changes:Triphasic color changes:
• PPallority = ‘’allority = ‘’WWhite’’ 2 p.hite’’ 2 p.
• CCyanosis = ‘’yanosis = ‘’BBlue’’ 1 p.lue’’ 1 p.
• RRedness = ‘’edness = ‘’RRed’’ 1 p.ed’’ 1 p.
Salehi I.Salehi I.
•SclerodermaScleroderma
Active Raynaud’s phenomenon
Salehi I.Salehi I.
•SclerodermaScleroderma
Raynaud phenomenon (RP):Raynaud phenomenon (RP):
• Diagnosis is only made by HistoryDiagnosis is only made by History
• Definite RPDefinite RP: : repeated episodes of biphasic repeated episodes of biphasic
color changes upon exposure to coldcolor changes upon exposure to cold
• Possible RP: Uniphasic color changes + Possible RP: Uniphasic color changes +
numbness or paresthesianumbness or paresthesia
• No RP: No color changes upon exposure No RP: No color changes upon exposure
to coldto cold
Salehi I.Salehi I.
•SclerodermaScleroderma
Raynaud phenomenon (RP):Raynaud phenomenon (RP):
• Primary (idiopathic, isolated):Primary (idiopathic, isolated):
Without a definable underling causeWithout a definable underling cause
An exaggeration of normal vasoconstriction to An exaggeration of normal vasoconstriction to
cold exposure cold exposure
• Secondary (pathologic):Secondary (pathologic):
With an underling disease or causeWith an underling disease or cause
Raynaud syndromeRaynaud syndrome
Salehi I.Salehi I.
•SclerodermaScleroderma
Secondary Raynaud ph:Secondary Raynaud ph:
• Systemic SclerosisSystemic Sclerosis
• SLE, other CTDSLE, other CTD
• Occlusive vascular diseaseOcclusive vascular disease
• Drugs/toxinsDrugs/toxins
• Hematologic abnormalitiesHematologic abnormalities
• Use of vibrating tools & vascular traumaUse of vibrating tools & vascular trauma
• FrostbiteFrostbite
Salehi I.Salehi I.
•SclerodermaScleroderma
Secondary Raynaud ph:Secondary Raynaud ph:
• Other Connective tissue diseases:Other Connective tissue diseases:
• MCTDMCTD
• Overlap syndromeOverlap syndrome
• PM/DMPM/DM
• RARA
• Sjogres’s syndromeSjogres’s syndrome
• UCTDUCTD
• VasculitisVasculitis
Salehi I.Salehi I.
•SclerodermaScleroderma
Secondary Raynaud ph:Secondary Raynaud ph:
• Occlusive vascular disease:Occlusive vascular disease:
• ArteriosclerosisArteriosclerosis
• AtheroemboliAtheroemboli
• Thromboangiitis obliteransThromboangiitis obliterans
• HypothyroidismHypothyroidism
Salehi I.Salehi I.
•SclerodermaScleroderma
• Drugs/toxins cause RPDrugs/toxins cause RP
• AmphetaminesAmphetamines
• Beta blockers, ClonidineBeta blockers, Clonidine
• Interferon-alphaInterferon-alpha
• Bleomycin, Cisplatin, VinblastineBleomycin, Cisplatin, Vinblastine
• Cocaine, NicotineCocaine, Nicotine
• CyclosporineCyclosporine
• Ergot, MethysergideErgot, Methysergide
• Vinyl chlorideVinyl chloride
Salehi I.Salehi I.
•SclerodermaScleroderma
Secondary Raynaud ph:Secondary Raynaud ph:
• Hematologic disease:Hematologic disease:
• Cold agglutinin diseaseCold agglutinin disease
• CryofibrinogenemiaCryofibrinogenemia
• CryoglobulinemiaCryoglobulinemia
• ParaproteinemiaParaproteinemia
• PolycythemiaPolycythemia
Salehi I.Salehi I.
•SclerodermaScleroderma
Primary Raynaud phenomenon:Primary Raynaud phenomenon:
• Age of onset: 15-30 yearsAge of onset: 15-30 years
• More common in femaleMore common in female
• Occur in multiple family membersOccur in multiple family members
• Spontaneous remission may occurSpontaneous remission may occur
• May be aggravated by: HTN, CVD, May be aggravated by: HTN, CVD,
atheroslerosis, and diabetes mellitusatheroslerosis, and diabetes mellitus
Salehi I.Salehi I.
•SclerodermaScleroderma
Diagnostic criteria of Primary RP:Diagnostic criteria of Primary RP:
• Symmetric episodic attacksSymmetric episodic attacks
• No evidence of peripheral vascular diseaseNo evidence of peripheral vascular disease
• No tissue gangrene, tissue injury, or digital No tissue gangrene, tissue injury, or digital
pittingpitting
• Negative nailfold capillary examinationNegative nailfold capillary examination
• Negative ANA and normal ESRNegative ANA and normal ESR
Salehi I.Salehi I.
•SclerodermaScleroderma
Normal nailfold Capillaroscopy
Salehi I.Salehi I.
•SclerodermaScleroderma
Clinical clues to suggest secondary RP:Clinical clues to suggest secondary RP:
• Later age of onset (>30-40 years)Later age of onset (>30-40 years)
• Male genderMale gender
• Painful RPPainful RP
• RP with digital ulceration and gangrene RP with digital ulceration and gangrene
• Asymmetric attacksAsymmetric attacks
• RP associated with other signs or symptomsRP associated with other signs or symptoms
• Abnormal lab. data: Abnormal lab. data: CBC, ESR, auto-antibodies,… CBC, ESR, auto-antibodies,…
Salehi I.Salehi I.
•SclerodermaScleroderma
Salehi I.Salehi I.
•SclerodermaScleroderma
Nailfold capillary microscopy:Nailfold capillary microscopy:
• Enlarged capillary loops orEnlarged capillary loops or
• Distorted capillary loops andDistorted capillary loops and
• Relative paucity of loops Relative paucity of loops
Suggest an underlying CTDSuggest an underlying CTD
• Enlargement associated with loss of Enlargement associated with loss of
capillariescapillaries
More suggestion of SSc More suggestion of SSc
Salehi I.Salehi I.
•SclerodermaScleroderma
‘’Slow’’ phase nailfold capillaries in lcSSc:Capillary dilatation
Salehi I.Salehi I.
•SclerodermaScleroderma
‘’Active’’ phase nailfold capillaries in dcSSc:Capillary dilatation and avascular areas
Salehi I.Salehi I.
•SclerodermaScleroderma
Salehi I.Salehi I.
•SclerodermaScleroderma
Approach to Raynaud phenomenon:Approach to Raynaud phenomenon:
• Step I: History and physical examination by GP Step I: History and physical examination by GP
• Step II: Nailfold capillary microscopy by GPStep II: Nailfold capillary microscopy by GP
If they are normal, then Primary RP is made by a GP, and no need If they are normal, then Primary RP is made by a GP, and no need
for laboratory tests. But if there are any abnormality or nailfold for laboratory tests. But if there are any abnormality or nailfold
capillary microscopy cannot perform capillary microscopy cannot perform
• Step III: Hx., Ph. Exam. and Nailfold capillary Step III: Hx., Ph. Exam. and Nailfold capillary
microscopy by Rheumatologistmicroscopy by Rheumatologist
• Step IV: Laboratory testsStep IV: Laboratory tests
Salehi I.Salehi I.
•SclerodermaScleroderma
Skin involvement:Skin involvement:• Universal feature of SSc Characterized by:Universal feature of SSc Characterized by:
– Skin thickening, hardness, and fixation Skin thickening, hardness, and fixation
• The fingers, hands and face are at firstThe fingers, hands and face are at first
• Prominent skin manifestation:Prominent skin manifestation: . Pruritus and edema in the early stages. Pruritus and edema in the early stages
. Sclerodactyly. Sclerodactyly
. Digital ulcers & pitting of fingertips. Digital ulcers & pitting of fingertips
. Telangiectasia. Telangiectasia
. Calcinosis cutis . Calcinosis cutis
Salehi I.Salehi I.
•SclerodermaScleroderma
Skin involvement:Skin involvement:• Diffuse tanningDiffuse tanning in the absence of sun in the absence of sun
exposureexposure
• VitiligoVitiligo-like hypopigmentation-like hypopigmentation
• ““Salt-and-pepper” appearance: Salt-and-pepper” appearance: – In scalp, upper back, chestIn scalp, upper back, chest
– Pigment loss spares the perifollicular areasPigment loss spares the perifollicular areas
• Dry skin, hair loss:Dry skin, hair loss:– Collagen accumulation causes oblitration of hair Collagen accumulation causes oblitration of hair
follicles, sweat & sebaceous glands follicles, sweat & sebaceous glands
Salehi I.Salehi I.
•SclerodermaScleroderma
The assessment of skin involvement:The assessment of skin involvement:
Estimation of:Estimation of:• Skin Skin thicknessthickness
• Pliability (Pliability (hardnesshardness))
• Fixation to underling structures (Fixation to underling structures (tetheringtethering))
The The modified Rodnan skin scoremodified Rodnan skin score::• In 17 distinct areas of the bodyIn 17 distinct areas of the body
• Score from 0 (nl) to 3 (most severe)Score from 0 (nl) to 3 (most severe)
Gold standard is skin palpation by RheumatologistGold standard is skin palpation by Rheumatologist
Ultrasonography & Durometer ?Ultrasonography & Durometer ?
Salehi I.Salehi I.
•SclerodermaScleroderma
Salehi I.Salehi I.
•SclerodermaScleroderma
Face:Face:• ““Mauskopf” faceMauskopf” face
– Shiny taut skinShiny taut skin
– Masklike & expressionlessMasklike & expressionless
– Decreased skin foldsDecreased skin folds
• MicrostomiaMicrostomia (fish mouth)(fish mouth)
• Perioral radial furrowingPerioral radial furrowing
• ““Beak-like” noseBeak-like” nose– Small sharp nose:Small sharp nose:
• Omega signOmega sign
• Matlike telangiectasesMatlike telangiectases
Salehi I.Salehi I.
•SclerodermaScleroderma
Hand involvement:Hand involvement:
Salehi I.Salehi I.
•SclerodermaScleroderma
‘’Slow’’ phase nailfold capillaries in lcSSc:Capillary dilatation
Salehi I.Salehi I.
•SclerodermaScleroderma
Hand involvement:Hand involvement:
• Sclerodactyly Sclerodactyly ::
– Thickening of finger skinThickening of finger skin
– Fibrosis of tendonsFibrosis of tendons
• Tapered fingersTapered fingers
• Transverse creases on the dorsum of Transverse creases on the dorsum of
the fingers disappearthe fingers disappear
Salehi I.Salehi I.
•SclerodermaScleroderma
Hand involvement:Hand involvement:
• Digital ulcerationsDigital ulcerations
– SuperinfectionSuperinfection
– OsteomyelitisOsteomyelitis
• ““Digital pits” Digital pits” = Pitting ulcers= Pitting ulcers
– Healing of ischemic fingertip ulcerationsHealing of ischemic fingertip ulcerations
Salehi I.Salehi I.
•SclerodermaScleroderma
Hand involvement:Hand involvement:
• Dissolution of terminal phalangesDissolution of terminal phalanges
– Loss of volar pads of the fingertips Loss of volar pads of the fingertips
– Resorption of the terminal phalangs:Resorption of the terminal phalangs:
– Acro-osteolysisAcro-osteolysis
• Periungual telangiectasiaPeriungual telangiectasia
Salehi I.Salehi I.
•SclerodermaScleroderma
Hand involvement:Hand involvement:
Salehi I.Salehi I.
•SclerodermaScleroderma
‘’Slow’’ phase nailfold capillaries in lcSSc:Capillary dilatation
Salehi I.Salehi I.
•SclerodermaScleroderma
Calcinosis cutis:Calcinosis cutis:
• Most common in patients with Most common in patients with lcSSc & positive ACAlcSSc & positive ACA
• CPPD depositionCPPD deposition
• Visualized on plain X-RaysVisualized on plain X-Rays
• Typical locations: finger pads, palms, extensor surfaces of Typical locations: finger pads, palms, extensor surfaces of
the forearms, olecranon & prepatellar bursaethe forearms, olecranon & prepatellar bursae
• Persistent firm, nontender subcutaneous lumpsPersistent firm, nontender subcutaneous lumps
• If ulcerate If ulcerate drainage of chalky white material drainage of chalky white material
Salehi I.Salehi I.
•SclerodermaScleroderma
Skin involvement:Skin involvement:
Neck sign
Barnett’s sign: Vertical striations in the skin with neck extension
Salehi I.Salehi I.
•SclerodermaScleroderma
Organ involvement:Organ involvement:• GastrointestinalGastrointestinal
• PulmonaryPulmonary
• RenalRenal
• CardiacCardiac
• MusculoskeletalMusculoskeletal
• OphthalmicOphthalmic
• OthersOthers
Salehi I.Salehi I.
•SclerodermaScleroderma
Gastrointestinal involvement:Gastrointestinal involvement:
• In In 90%90% of cases of cases
• Any part of GIAny part of GI
• About 50% symptomaticAbout 50% symptomatic
• Esophageal: most commonEsophageal: most common
• Pathology:Pathology:
. . Smooth muscle atrophySmooth muscle atrophy
. . Gut wall fibrosisGut wall fibrosis
Salehi I.Salehi I.
•SclerodermaScleroderma
Oral involvement:Oral involvement: Micro-ostia (Micro-ostia (fish mouthfish mouth))
Rigidity of tongue with short frenulumRigidity of tongue with short frenulum
Rigidity & tenderness of oral mucosaRigidity & tenderness of oral mucosa
Malalignment of teethMalalignment of teeth
Oropharyngeal dysphagiaOropharyngeal dysphagia: 25%: 25%
Oropharyngeal incoordination: 25%Oropharyngeal incoordination: 25%
Sjogren’s syndromeSjogren’s syndrome
Impaired mastication & deglutitionImpaired mastication & deglutition
Salehi I.Salehi I.
•SclerodermaScleroderma
Esophageal involvement (90%):Esophageal involvement (90%):
Lower two-thirds of Esophagus:Lower two-thirds of Esophagus:
• Reduced or No peristalsisReduced or No peristalsis
• Dilated lumenDilated lumen
• Decreased LES toneDecreased LES tone
GERD: pyrosis GERD: pyrosis
Dysmotility: dysphagiaDysmotility: dysphagia
Hiatal herniaHiatal hernia
Salehi I.Salehi I.
•SclerodermaScleroderma
Esophageal involvement (90%):Esophageal involvement (90%):
In past: Manometry, Barium swallowIn past: Manometry, Barium swallow
Nowadays: Esophagoscopy if:Nowadays: Esophagoscopy if: Complications are suspectedComplications are suspected
Persistent symptoms after PPI therapyPersistent symptoms after PPI therapy
Esophagoscopy:Esophagoscopy: Reflux esophagitis, candidiasisReflux esophagitis, candidiasis
Barrett’s esophagus, LE strictureBarrett’s esophagus, LE stricture
Salehi I.Salehi I.
•SclerodermaScleroderma
Gastric involvement:Gastric involvement:
Gastric emptying: delayedGastric emptying: delayed
Mucosal telangiectasia:Mucosal telangiectasia:
• Watermelon stomachWatermelon stomach
• Upper GI bleedingUpper GI bleeding
Gastric antral venous ectasia (Gastric antral venous ectasia (GAVEGAVE):):
• Unexplained IDAUnexplained IDA
Gastroparesis: rareGastroparesis: rare
Salehi I.Salehi I.
•SclerodermaScleroderma
Watermelon stomachSalehi I.Salehi I.
•SclerodermaScleroderma
Small bowel involvement:Small bowel involvement:
Reduced peristalsisReduced peristalsis
• Abdominal distensionAbdominal distension
• Bacterial overgrowthBacterial overgrowth
• Intermittent diarrhea-constipationIntermittent diarrhea-constipation
• MalabsorptionMalabsorption
• Pseudo-obstruction & PerforationPseudo-obstruction & Perforation
• Pneumatosis cystoides intestinalisPneumatosis cystoides intestinalis
• VolvulusVolvulus
• Pseudo-obstructionPseudo-obstruction
• Bacterial overgrowthBacterial overgrowth
• Pneumatosis intestinalisPneumatosis intestinalis
• Rectal prolaps, incontinenceRectal prolaps, incontinence
Salehi I.Salehi I.
•SclerodermaScleroderma
Colonic disease:Colonic disease:
Anorectum: most commonAnorectum: most common
• Fecal incontinenceFecal incontinence
• Rectal prolapseRectal prolapse
Gastrocolic reflex: absentGastrocolic reflex: absent
Wide-mouthed diverticuliWide-mouthed diverticuli
ConstipationConstipation
Colonic perforationColonic perforation
Colonic infarctionColonic infarction
Salehi I.Salehi I.
•SclerodermaScleroderma
Pulmonary involvement:Pulmonary involvement:
• In most patients with SSc: In most patients with SSc: 70%70%
• Leading cause of deathLeading cause of death
• Two main types:Two main types:
Interstitial Lung Disease (Interstitial Lung Disease (ILDILD))
Pulmonary Arterial Hypertension (Pulmonary Arterial Hypertension (PAHPAH))
Salehi I.Salehi I.
•SclerodermaScleroderma
Pulmonary involvement:Pulmonary involvement: Less common types:Less common types:
• Aspiration pneumoniaAspiration pneumonia
• Pulmonary hemorrhagePulmonary hemorrhage
• Obliterative BronchiolitisObliterative Bronchiolitis
• Extraparenchymal restrictive lung diseaseExtraparenchymal restrictive lung disease
• Spontaneous pneumothoraxSpontaneous pneumothorax
• Drug induced lung diseaseDrug induced lung disease
• Lung cancer (Bronchoalveolar Carcinoma)Lung cancer (Bronchoalveolar Carcinoma)
Salehi I.Salehi I.
•SclerodermaScleroderma
Pulmonary involvement:Pulmonary involvement: Common presentations:Common presentations:
• DOE: most commonDOE: most common
• Chronic dry cough: commonChronic dry cough: common
• Reduced exercise tolerance, fatigueReduced exercise tolerance, fatigue
• Chest pain: uncommonChest pain: uncommon
• Hemoptysis: RareHemoptysis: Rare
• Asymptomatic: 1/3Asymptomatic: 1/3
• Basal “Velcro” cracklesBasal “Velcro” crackles
Salehi I.Salehi I.
•SclerodermaScleroderma
Interstitial lung disease:Interstitial lung disease:
• Up to 90% in autopsyUp to 90% in autopsy
• Up to 85% in HRCTUp to 85% in HRCT
• Up to 43% clinically: “Velcro” cracklesUp to 43% clinically: “Velcro” crackles
• CXR-PA: Lower lobes reticular patternCXR-PA: Lower lobes reticular pattern
Salehi I.Salehi I.
•SclerodermaScleroderma
Interstitial lung disease:Interstitial lung disease:
HRCT: one or combination of below patternsHRCT: one or combination of below patterns
• Reticular linear opacitiesReticular linear opacities
• Nodular opacitiesNodular opacities
• Honey comb cystic changesHoney comb cystic changes
• Ground glass opacificationGround glass opacification
Salehi I.Salehi I.
•SclerodermaScleroderma
Interstitial lung disease:Interstitial lung disease:
• FEV-1: UnaffectedFEV-1: Unaffected
• FVC: DecreasedFVC: Decreased
• FEV-1/FVC: Normal or increasedFEV-1/FVC: Normal or increased
• DLCO: DecreasedDLCO: Decreased
Salehi I.Salehi I.
•SclerodermaScleroderma
Interstitial lung disease:Interstitial lung disease:
Risk factors for ILD:Risk factors for ILD:
• Male genderMale gender
• African-American raceAfrican-American race
• Diffuse cutaneous SScDiffuse cutaneous SSc
• Severe GERDSevere GERD
• Presence of anti-topoisomerase-IPresence of anti-topoisomerase-I
• Low FVC or DLCO at initial presentationLow FVC or DLCO at initial presentation
Salehi I.Salehi I.
•SclerodermaScleroderma
Interstitial lung disease:Interstitial lung disease:
Rapid progressive ILDRapid progressive ILD
• Within the first 3 years of diseaseWithin the first 3 years of disease
• Significant DOESignificant DOE
• Extensive “Velcro” cracklesExtensive “Velcro” crackles
• Extensive pattern in HRCT Extensive pattern in HRCT
• The FVC can decline by 30%/yearThe FVC can decline by 30%/year
Salehi I.Salehi I.
•SclerodermaScleroderma
Interstitial lung disease:Interstitial lung disease:
Bronchoalveolar lavage (BAL):Bronchoalveolar lavage (BAL):
• PMN > 2% &/or Eosinophils > 3% is correlated with more PMN > 2% &/or Eosinophils > 3% is correlated with more
extensive ILD in HRCTextensive ILD in HRCT
Serum level of KL-6:Serum level of KL-6:
• Measurement of KL-6, a glycoprotein found in type II Measurement of KL-6, a glycoprotein found in type II
pneumocytes and alveolar macrophages is a biomarker pneumocytes and alveolar macrophages is a biomarker
for the detection and serial monitoring of ILD in SScfor the detection and serial monitoring of ILD in SSc
Salehi I.Salehi I.
•SclerodermaScleroderma
Salehi I.Salehi I.
•SclerodermaScleroderma
Salehi I.Salehi I.
•SclerodermaScleroderma
Pulmonary arterial hypertension (PAH):Pulmonary arterial hypertension (PAH):
Definition: Definition:
• Mean Pulmonary arterial pressure > 25 mmHgMean Pulmonary arterial pressure > 25 mmHg
• Pulmonary capillary wedge pressure < 15 mmHgPulmonary capillary wedge pressure < 15 mmHg
In 10-15% of patients with SScIn 10-15% of patients with SSc
Development of RHFDevelopment of RHF
DOE, Angina, Exertional near-syncopeDOE, Angina, Exertional near-syncope
With significant mortalityWith significant mortality
Salehi I.Salehi I.
•SclerodermaScleroderma
Pulmonary arterial hypertension (PAH):Pulmonary arterial hypertension (PAH):
Risk factors of PAH:Risk factors of PAH:
• Limited cuteneous SSc Limited cuteneous SSc
• Positive ACAPositive ACA
• Late age at disease onsetLate age at disease onset
• Severe Raynaud’s ph.Severe Raynaud’s ph.
• Anti U1-RNP, U3-RNP (Fibrillarin) and B23Anti U1-RNP, U3-RNP (Fibrillarin) and B23
Salehi I.Salehi I.
•SclerodermaScleroderma
Pulmonary arterial hypertension (PAH):Pulmonary arterial hypertension (PAH):
Doppler Echocardiography:Doppler Echocardiography:
• Used as screeningUsed as screening
• PA systolic pressure > 40 mmHg at rest PA systolic pressure > 40 mmHg at rest
suggest PAHsuggest PAH
Serum level of brain natriuretic peptide (BNP):Serum level of brain natriuretic peptide (BNP):
• Used as screening and monitoring of PAHUsed as screening and monitoring of PAH
Salehi I.Salehi I.
•SclerodermaScleroderma
Renal involvement:Renal involvement:
• 50% clinical involvement50% clinical involvement
• 60-80% in autopsy60-80% in autopsy
• Sclerodermal Renal Crisis (SRC)Sclerodermal Renal Crisis (SRC)
– The most dreaded complication of SScThe most dreaded complication of SSc
– Almost always within first 4 years of Almost always within first 4 years of
disease disease
Salehi I.Salehi I.
•SclerodermaScleroderma
Sclerodermal Renal Crisis: Sclerodermal Renal Crisis: • In 10-20% of dcSScIn 10-20% of dcSSc
• ARF with NL U/AARF with NL U/A
• New & a few Pr or RBC or granular casts in U/ANew & a few Pr or RBC or granular casts in U/A
• Abrupt onset of Marked HTN Abrupt onset of Marked HTN (10% NL HTN):(10% NL HTN):
– Headache, blurred vision, chest painHeadache, blurred vision, chest pain
• Pericarditis, CHFPericarditis, CHF
• Microangiopathic hemolytic anemiaMicroangiopathic hemolytic anemia
• Activated RAA system + nephrosclerosisActivated RAA system + nephrosclerosis
Salehi I.Salehi I.
•SclerodermaScleroderma
Risk factors of SRC:Risk factors of SRC:
• Diffuse, advanced skin involvementDiffuse, advanced skin involvement
• Male genderMale gender
• African American raceAfrican American race
• Glucocorticoid use (MDS-HDS)Glucocorticoid use (MDS-HDS)
• Anti RNA polymeras I & IIIAnti RNA polymeras I & III
• CyclosporineCyclosporine
Salehi I.Salehi I.
•SclerodermaScleroderma
Screening for SRC:Screening for SRC:
• In high risk pt.: Daily home BP measurementIn high risk pt.: Daily home BP measurement
• In other pt.: Biweekly BP measurementIn other pt.: Biweekly BP measurement
• In all pt.: Plasma Cr & Urine Pr Checking every In all pt.: Plasma Cr & Urine Pr Checking every
3-6 months3-6 months
Salehi I.Salehi I.
•SclerodermaScleroderma
Alarm signs of impending SRC:Alarm signs of impending SRC:
• Palpable tendon friction rubsPalpable tendon friction rubs
• Pericardial effusionPericardial effusion
– Pericardial friction rubPericardial friction rub
• New unexplained anemiaNew unexplained anemia
• New unexplained thrombocytopeniaNew unexplained thrombocytopenia
Salehi I.Salehi I.
•SclerodermaScleroderma
Outcome of SRC:Outcome of SRC:
• Oliguria or Cr > 3 mg/dl at presentation predicts Oliguria or Cr > 3 mg/dl at presentation predicts
poor outcome, with permanent hemodialysis poor outcome, with permanent hemodialysis
and high mortalityand high mortality
• Using short-acting ACE inhibitors to achieve Using short-acting ACE inhibitors to achieve
adequate BP control before the onset of renal adequate BP control before the onset of renal
failure results in improved prognosisfailure results in improved prognosis
Salehi I.Salehi I.
•SclerodermaScleroderma
Lung CancerLung Cancer
• The risk is increased similarly in both The risk is increased similarly in both
lcSSc & dcSSclcSSc & dcSSc
• The risk is 5 x nl populationThe risk is 5 x nl population
• 1/3 of cancer in SSc1/3 of cancer in SSc
Salehi I.Salehi I.
•SclerodermaScleroderma
Other CancersOther Cancers
• TongueTongue
• BreastBreast
• Esophagus ( Barrett’s Esophagus ( Barrett’s Adenocarcinoma) Adenocarcinoma)
Salehi I.Salehi I.
•SclerodermaScleroderma
Cardiac involvement:Cardiac involvement:
• In dcSSc more than lcSScIn dcSSc more than lcSSc
• Within 3 years of the onset of skin thickeningWithin 3 years of the onset of skin thickening
• Often clinically silentOften clinically silent
• All layers of heart may be involvedAll layers of heart may be involved
Salehi I.Salehi I.
•SclerodermaScleroderma
Cardiac involvement:Cardiac involvement:
• Secondary to systemic HTN or PAH: Secondary to systemic HTN or PAH:
– most commonmost common
– LVH, RVH, and CHFLVH, RVH, and CHF
• Pericarditis Pericarditis ++ effusion: effusion: PE alarm sign of SRCPE alarm sign of SRC
• Myocardial fibrosisMyocardial fibrosis, Myocarditis, Myocarditis
• Valvular regurgitationValvular regurgitation
Salehi I.Salehi I.
•SclerodermaScleroderma
Cardiac involvement:Cardiac involvement:
• Angina pectorisAngina pectoris
• Conduction disturbancesConduction disturbances
• Arrhythmias: Atrial & Ventricular tachycardiasArrhythmias: Atrial & Ventricular tachycardias
• Tissue Doppler Echo (TDE) & Cardiac MRITissue Doppler Echo (TDE) & Cardiac MRI
• Thallium perfusion studiesThallium perfusion studies
• Serum level of NT-Pro-BNP as a marker of primary Serum level of NT-Pro-BNP as a marker of primary
cardiac involvement cardiac involvement
Salehi I.Salehi I.
•SclerodermaScleroderma
Musculoskeletal disease:Musculoskeletal disease:
In early stage of disease:In early stage of disease:
• CTS: common & may be presenting featureCTS: common & may be presenting feature
• Edema & swelling of handsEdema & swelling of hands
• Generalized arthralgia-myalgiaGeneralized arthralgia-myalgia
• Hand joints: most commonHand joints: most common
Salehi I.Salehi I.
•SclerodermaScleroderma
Musculoskeletal disease:Musculoskeletal disease:
• Stiff joints in dcSSc:Stiff joints in dcSSc:
Elbow, Shoulder, KneeElbow, Shoulder, Knee
• Large joint contracturesLarge joint contractures
• Tendon friction rubsTendon friction rubs
Fingers, wrist, elbow, knee and ankleFingers, wrist, elbow, knee and ankle
• True arthritis uncommonTrue arthritis uncommon
• Erosive polyarthritis of hands: may be Erosive polyarthritis of hands: may be
Salehi I.Salehi I.
•SclerodermaScleroderma
Musculoskeletal disease:Musculoskeletal disease:
Muscle weakness: commonMuscle weakness: common
• Disuse atrophyDisuse atrophy
• MalnutritionMalnutrition
• Overlap with polymyositisOverlap with polymyositis
• MyopathiesMyopathies
Salehi I.Salehi I.
•SclerodermaScleroderma
Musculoskeletal disease:Musculoskeletal disease:•
• Erosive polyarthritis with positive RF: Erosive polyarthritis with positive RF:
overlap of RA & Scloverlap of RA & Scl
• HA arthropathyHA arthropathy
• OA of DIP & CMC1OA of DIP & CMC1
• Acro-osteolysis, resorption of mandibular Acro-osteolysis, resorption of mandibular
condyles, osteolysis of ribs and distal claviclescondyles, osteolysis of ribs and distal clavicles
Salehi I.Salehi I.
•SclerodermaScleroderma
Neurologic involvement:Neurologic involvement:
NeuropathiesNeuropathies• Cranial, Peripheral, AutonomicCranial, Peripheral, Autonomic
• Entrapment, CutaneousEntrapment, Cutaneous
Trigeminal neuralgiaTrigeminal neuralgia
CNS: uncommon to rareCNS: uncommon to rare• Headache, Seizures,Headache, Seizures,
• Stroke, Vascular diseaseStroke, Vascular disease
• Radiculopathy, myelopathyRadiculopathy, myelopathy
Salehi I.Salehi I.
•SclerodermaScleroderma
Genitourinary involvement:Genitourinary involvement:
In men:In men:• Erectile dysfunction: 80%Erectile dysfunction: 80%• Male impotenceMale impotence
In women:In women:• Sexual dysfunctionSexual dysfunction• Vaginal drynessVaginal dryness• Constriction of the vaginal introitusConstriction of the vaginal introitus• Dyspareunia: > 1/2Dyspareunia: > 1/2
Salehi I.Salehi I.
•SclerodermaScleroderma
• Sjogren’s syndromeSjogren’s syndrome
• HypothyroidismHypothyroidism
• PBC: lcSScPBC: lcSSc
• Difficult pregnancy: dcSScDifficult pregnancy: dcSSc
Salehi I.Salehi I.
•SclerodermaScleroderma
CREST CREST syndrome :syndrome :
CCalcinosisalcinosis
RRaynaud’s ph.aynaud’s ph.
EEsophageal dysmotilitysophageal dysmotility
SSclerodactylyclerodactyly
TTelangiectasiaelangiectasia
Salehi I.Salehi I.
•SclerodermaScleroderma
Lab. Data:Lab. Data: CBC: AnemiaCBC: Anemia
ESRESR
Renal FT, Liver FTRenal FT, Liver FT
FANA: 95%, speckledFANA: 95%, speckled
• Scl-70Scl-70
• ACAACA
CXRCXR
Salehi I.Salehi I.
•SclerodermaScleroderma
Lab. Data:Lab. Data:
• AOCD; mild, most commonAOCD; mild, most common
• IDA: GAVE, chronic esophagitisIDA: GAVE, chronic esophagitis
• Macrocytic anemia: Macrocytic anemia:
• B12, Folate deficiencyB12, Folate deficiency
• Drugs: MTXDrugs: MTX
• Microangiopathic hemolytic anemia:Microangiopathic hemolytic anemia:
• SRCSRC
Salehi I.Salehi I.
•SclerodermaScleroderma
Lab. Data:Lab. Data:
• Pancytopenia:Pancytopenia:
• DrugsDrugs
• SRCSRC
• MalignancyMalignancy
• Elevated ESR:Elevated ESR:
• MyositisMyositis
• MalignancyMalignancy
Salehi I.Salehi I.
•SclerodermaScleroderma
Lab. Data:Lab. Data:
AntitopoisomeraseAntitopoisomerase I (Scl-70)I (Scl-70)
• Highly specific for SScHighly specific for SSc
• High risk of ILDHigh risk of ILD
• Associated with Associated with dcSScdcSSc
Anti-centromere antibodies (ACA)Anti-centromere antibodies (ACA)
• Associated with Associated with lcSSclcSSc
Salehi I.Salehi I.
•SclerodermaScleroderma
Lab. Data:Lab. Data:
AntiPM-Scl: PM + SclAntiPM-Scl: PM + Scl
AntiU3-RNP (Fibrillarin): SSc + PAHAntiU3-RNP (Fibrillarin): SSc + PAH
Anti RNA polymerase I & III: only in SSc Anti RNA polymerase I & III: only in SSc
Anti RNA polymerase II: in SLE or SScAnti RNA polymerase II: in SLE or SSc
RF: 25%RF: 25%
Salehi I.Salehi I.
•SclerodermaScleroderma
Attention please:• Scl-70Scl-70 & &
• ACAACA & &
• Anti-RNA polymerase III Anti-RNA polymerase III antibody testsantibody tests
are highly specific (> 99.5%) but only are highly specific (> 99.5%) but only moderately sensitive (20-50%)moderately sensitive (20-50%)
• Over 95% of SSc patients have at least Over 95% of SSc patients have at least one autoantibodies one autoantibodies
Salehi I.Salehi I.
•SclerodermaScleroderma
Lab. Data:Lab. Data:• GI EndoscopyGI Endoscopy
• Doppler EchocardiographyDoppler Echocardiography
• HRCT of lungHRCT of lung
• Hand X-RayHand X-Ray
• Manometry, DlcoManometry, Dlco
• Spirometry, PletismographySpirometry, Pletismography
• Thyroid FT Thyroid FT
• Skin biopsy Skin biopsy
Salehi I.Salehi I.
•SclerodermaScleroderma
Skin biopsy:Skin biopsy:
• Not necessary for diagnosis of SScNot necessary for diagnosis of SSc
• Only done in doubtful casesOnly done in doubtful cases
• For DD with Scleroderma-like disordersFor DD with Scleroderma-like disorders
• May be necessary for localized SclerodermaMay be necessary for localized Scleroderma
• Should include subcutaneous tissue, fascia, Should include subcutaneous tissue, fascia,
and muscleand muscle
Salehi I.Salehi I.
•SclerodermaScleroderma
Scleroderma-like disorders:Scleroderma-like disorders:• Scleredema Scleredema • ScleromyxedemaScleromyxedema• Diabetes MellitusDiabetes Mellitus• HypothyroidismHypothyroidism• Nephrogenic systemic fibrosisNephrogenic systemic fibrosis• AmyloidosisAmyloidosis• Eosinophilic fasciitisEosinophilic fasciitis• Chronic GVHDChronic GVHD
Salehi I.Salehi I.
•SclerodermaScleroderma
Limited Cutaneous SSc (lcSSc):Limited Cutaneous SSc (lcSSc):
• Raynaud’s ph. For yearsRaynaud’s ph. For years
• Acro-facial skin sclerosisAcro-facial skin sclerosis
• Dilated nailfold capillary loops( Dilated nailfold capillary loops( no drop-outno drop-out ) )
• Accompanied by CREST syndromeAccompanied by CREST syndrome
• Pulmonary Artery Hypertension( PAH )Pulmonary Artery Hypertension( PAH )
• ILD lately & SRC rarely occursILD lately & SRC rarely occurs
• ACAACA: 70 - 80% : 70 - 80%
Salehi I.Salehi I.
•SclerodermaScleroderma
Diffuse Cutaneous SSc (dcSSc):Diffuse Cutaneous SSc (dcSSc):
• Raynaud’s ph. Followed, within one year, by Raynaud’s ph. Followed, within one year, by
puffy skin changespuffy skin changes
• TrunkalTrunkal & acro-facial & acro-facial skin sclerosisskin sclerosis
• Tendon friction rubsTendon friction rubs
• Nailfold capillary dilatation (with drop-out)Nailfold capillary dilatation (with drop-out)
• Early & significant incidence of SRC, ILD, GI & Early & significant incidence of SRC, ILD, GI &
cardiac diseasecardiac disease
• Anti-Scl-70Anti-Scl-70: 30%: 30%
Salehi I.Salehi I.
•SclerodermaScleroderma
Pre-SclerodermaPre-Scleroderma
Subclinical SclerodermaSubclinical Scleroderma
Early Scleroderma Early Scleroderma
Salehi I.Salehi I.
•SclerodermaScleroderma
Pre-Scleroderm Pre-Scleroderm
• Raynaud’s phenomenon plusRaynaud’s phenomenon plus
• Nailfold capillary changes &/orNailfold capillary changes &/or
• Autoantibodies:Autoantibodies:• Scl-70Scl-70
• ACAACA
• Anti-RNA polymeraseAnti-RNA polymerase
• No skin involvementNo skin involvement
Salehi I.Salehi I.
•SclerodermaScleroderma
Diagnosis of SSc:Diagnosis of SSc:
• Clinical: UponClinical: Upon
History &History &
Physical examinationPhysical examination
• No skin biopsy: only for No skin biopsy: only for
Localized Scl.Localized Scl.
DD with Scl. Like disordersDD with Scl. Like disorders
Salehi I.Salehi I.
•SclerodermaScleroderma
Diagnosis of SSc:Diagnosis of SSc: Combination of Combination of skin induration plus skin induration plus >> 1 of: 1 of:
• Heartburn &/or dysphagia of new onsetHeartburn &/or dysphagia of new onset
• Acute onset of HTN & renal failureAcute onset of HTN & renal failure
• DOE + ILD, or PAHDOE + ILD, or PAH
• Diarrhea with malabsorptionDiarrhea with malabsorption
• Facial, lip, or hand telangiectasiaFacial, lip, or hand telangiectasia
• Digital infarctions & or pitting ulcerDigital infarctions & or pitting ulcer
• Erectile dysfunctionErectile dysfunction
Salehi I.Salehi I.
•SclerodermaScleroderma
Attention please:
The presence of :The presence of :
• Calcinosis cutisCalcinosis cutis
• HyperpigmentationHyperpigmentation &/or &/or Skin Skin
telangiectasia andtelangiectasia and
• FacialFacial and and FingersFingers features features
Can differentiate SSc from other DDCan differentiate SSc from other DD
Salehi I.Salehi I.
•SclerodermaScleroderma
Prognosis & Mortality:Prognosis & Mortality:
Mortality rate:Mortality rate:• in dcSSc # 5-8 fold higher than nl populationin dcSSc # 5-8 fold higher than nl population• In lcSSc # 2 foldIn lcSSc # 2 fold
The most common cause of death in The most common cause of death in dcSSc:dcSSc:• Pulmonary fibrosis &/or PAHPulmonary fibrosis &/or PAH• SRCSRC• CardiacCardiac
Salehi I.Salehi I.
•SclerodermaScleroderma
Management:Management:
• No cure, No remissionNo cure, No remission• Localized or Systemic Scl.Localized or Systemic Scl.• Which type of systemic Scl.Which type of systemic Scl.• Nonpharmacologic therapyNonpharmacologic therapy• PharmacologicPharmacologic• Symptomatic therapySymptomatic therapy• Systemic therapy:Systemic therapy:
• Vascular + Immunologic + FibroticVascular + Immunologic + Fibrotic• Minor vs majorMinor vs major
Salehi I.Salehi I.
•SclerodermaScleroderma
Attention please:
• Elucidation of the precise interplay Elucidation of the precise interplay
between the Vascular, Immunologic between the Vascular, Immunologic
and Fibrotic components of SSc is and Fibrotic components of SSc is
likely to be an important first step likely to be an important first step
towards more effective therapytowards more effective therapy
Salehi I.Salehi I.
•SclerodermaScleroderma
Disease modifying therapy:
• Immunosuppressive therapy:Immunosuppressive therapy:
– Glucocorticoids (LDS)Glucocorticoids (LDS)
– MTXMTX
– Mycophenolate mofetilMycophenolate mofetil
– CyclophosphamideCyclophosphamide
– Autologous stem cell transplantationAutologous stem cell transplantation
Salehi I.Salehi I.
•SclerodermaScleroderma
Disease modifying therapy:
• Anti-fibrotic therapy:Anti-fibrotic therapy:
– D-penicillamine:D-penicillamine:
• Standard-dose: 750 mg/dayStandard-dose: 750 mg/day
• Low-dose: 125 mg qodLow-dose: 125 mg qod
Salehi I.Salehi I.
•SclerodermaScleroderma
Disease modifying therapy:
Vascular therapy:Vascular therapy:• Calcium channel blockers: Calcium channel blockers: DiltiazemDiltiazem• Angiotensin II receptor blockers: Angiotensin II receptor blockers: LosartanLosartan• Alpha-1 blocker: prazocinAlpha-1 blocker: prazocin• 5-phosphodiesterase inhibitors: 5-phosphodiesterase inhibitors: SildenafilSildenafil• SSRI: SSRI: FluoxetineFluoxetine• Topical nitroglycerineTopical nitroglycerine• IV prostaglandine: IV prostaglandine: IloprostIloprost• Anti-platelet agent: low-dose Anti-platelet agent: low-dose AspirinAspirin• Endothein-1 receptor antagonist: Endothein-1 receptor antagonist: BosentanBosentan
Salehi I.Salehi I.
•SclerodermaScleroderma
Pulmonary therapy:
Severe acute ILD:Severe acute ILD:
• Cyclophosphamide plusCyclophosphamide plus
• Medium dose GlucocorticoidsMedium dose Glucocorticoids
Symptomatic PAH:Symptomatic PAH:
• BosentanBosentan
• SildenafilSildenafil
Salehi I.Salehi I.
•SclerodermaScleroderma
Gastrointestinal therapy: GERD: PPIGERD: PPI• Omeprazole, PantozolOmeprazole, Pantozol• Nexium (esomeprazole)Nexium (esomeprazole)
GI bleeding: Watermelon, GAVEGI bleeding: Watermelon, GAVE• Laser photocoagulationLaser photocoagulation
Bacterial overgrowth:Bacterial overgrowth:• MetronidazoleMetronidazole• Erythromycin & TetracyclineErythromycin & Tetracycline
Chronic hypomotility:Chronic hypomotility:• OctreotideOctreotide
Salehi I.Salehi I.
•SclerodermaScleroderma
Scleroderma Renal Crisis therapy:
ACE inhibitors: 90% of casesACE inhibitors: 90% of cases
Hemodialysis: 2/3 of casesHemodialysis: 2/3 of cases
• In ½ of cases: recoveryIn ½ of cases: recovery
• In ½ of cases who are unable to D/C dialysis In ½ of cases who are unable to D/C dialysis
after 2 years: Renal transplantationafter 2 years: Renal transplantation
• Recurrency of SRC in transplanted kidney is rare Recurrency of SRC in transplanted kidney is rare
Salehi I.Salehi I.
•SclerodermaScleroderma
Symptomatic therapy:
• PruritusPruritus
• Dry skinDry skin
• DyspareuniaDyspareunia
• Facial telangiectasisFacial telangiectasis
• DOEDOE
Salehi I.Salehi I.
•SclerodermaScleroderma
Salehi I.Salehi I.
•SclerodermaScleroderma